- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01999192
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis (986)
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX alone.
The overall study duration is 24 weeks followed by a 24 week extension phase.
Přehled studie
Detailní popis
The planned clinical study 986 (TREAT 2b) is a 24-week study in patients with Active rheumatoid arthritis (RA) who have had an inadequate response to Methotrexate (MTX) alone. The main phase of this study is followed by a 24-week extension phase for subjects meeting the respective entry criteria. Patients will be randomized to one of three different Active treatment groups or Placebo. The primary efficacy variable is the proportion of subjects with an ACR20 response after 12 weeks of double blinded treatment with the study medication based on observed cases in the FAS.
At Week 12, all subjects who had a minimum improvement of at least 20% (from baseline) in their tender joint count (TJC) and swollen joint count (SJC) continued on the same treatment. Subjects who had not demonstrated an improvement of at least 20% of TJC and SJC were assessed as non-responders. Non-responders who received placebo were randomized to an active treatment dose in a blinded manner. Non-responders who received active treatment were rolled up to the next highest dose in a blinded manner, apart from those already on the highest dose. These subjects remained on the highest dose.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Plovdiv, Bulharsko
- Study site 01
-
Plovdiv, Bulharsko
- Study site 06
-
Sofia, Bulharsko
- Study site 02
-
Sofia, Bulharsko
- Study site 04
-
Sofia, Bulharsko
- Study Site 07
-
Stara Zagora, Bulharsko
- Study site 05
-
Varna, Bulharsko
- Study site 03
-
-
-
-
-
Tallinn, Estonsko
- Study site 01
-
-
-
-
Quebec
-
Rimouski, Quebec, Kanada
- Study site 02
-
St-Jérôme, Quebec, Kanada
- Study site 01
-
-
-
-
-
Kaunas, Litva
- Study site 01
-
Vilnus, Litva
- Study site 02
-
-
-
-
-
Balatonfüred, Maďarsko
- Study site 03
-
Budapest, Maďarsko
- Study site 02
-
Budapest, Maďarsko
- Study site 04
-
Budapest, Maďarsko
- Study site 05
-
Gyula, Maďarsko
- Study site 06
-
Veszprem, Maďarsko
- Study site 01
-
-
-
-
-
Chihuahua, Mexiko
- Study site 02
-
Distrito Federal, Mexiko
- Study site 03
-
-
Distrito Federal
-
Mexico, Distrito Federal, Mexiko
- Study site 05
-
Mexico, Distrito Federal, Mexiko
- Study Site 08
-
-
Guanajuato
-
Leon, Guanajuato, Mexiko
- Study site 06
-
-
-
-
-
Berlin, Německo
- Study site 03
-
Frankfurt, Německo
- Study site 04
-
Muenchen, Německo
- Study site 06
-
Ratingen, Německo
- Study site 02
-
Zerbst, Německo
- Study site 01
-
-
-
-
-
Bialystok, Polsko
- Study Site 08
-
Bydgoszcz, Polsko
- Study site 05
-
Elblag, Polsko
- Study site 10
-
Gdynia, Polsko
- Study site 04
-
Katowice, Polsko
- Study site 02
-
Krakow, Polsko
- Study site 03
-
Krakow, Polsko
- Study site 06
-
Poznan, Polsko
- Study site 09
-
Warszawa, Polsko
- Study site 01
-
Warszawa, Polsko
- Study Site 07
-
-
-
-
-
Kemerovo, Ruská Federace
- Study Site 08
-
Kemerovo, Ruská Federace
- Study site 11
-
Kursk, Ruská Federace
- Study site 04
-
Moscow, Ruská Federace
- Study site 03
-
Moscow, Ruská Federace
- Study Site 07
-
Moscow, Ruská Federace
- Study site 10
-
Omsk, Ruská Federace
- Study site 05
-
Saratov, Ruská Federace
- Study site 09
-
Smolensk, Ruská Federace
- Study site 06
-
Tomsk, Ruská Federace
- Study site 01
-
Yaroslavl, Ruská Federace
- Study site 02
-
-
-
-
-
Bratislava, Slovensko
- Study site 03
-
Kosice - Saca, Slovensko
- Study site 04
-
Lucenec, Slovensko
- Study site 05
-
Povazska Bystrica, Slovensko
- Study site 02
-
Rimavska Sobota, Slovensko
- Study site 01
-
-
-
-
Arizona
-
Paradise Valley, Arizona, Spojené státy, 85253
- Study Site 07
-
-
Illinois
-
Springfield, Illinois, Spojené státy, 62704
- Study site 01
-
-
Nebraska
-
Lincoln, Nebraska, Spojené státy, 68516
- Study site 03
-
-
New Jersey
-
Clifton, New Jersey, Spojené státy, 07012
- Study site 02
-
-
South Carolina
-
North Charleston, South Carolina, Spojené státy, 29406
- Study site 04
-
-
Tennessee
-
Jackson, Tennessee, Spojené státy, 38305
- Study site 05
-
-
Texas
-
Houston, Texas, Spojené státy, 77004
- Study site 09
-
Katy, Texas, Spojené státy, 77450
- Study site 10
-
-
-
-
-
Belgrade, Srbsko
- Study site 01
-
Belgrade, Srbsko
- Study site 02
-
Belgrade, Srbsko
- Study site 04
-
Niska Banja, Srbsko
- Study site 03
-
-
-
-
-
Donetsk, Ukrajina
- Study Site 08
-
Kharkiv, Ukrajina
- Study site 01
-
Kharkiv, Ukrajina
- Study site 02
-
Kyiv, Ukrajina
- Study site 03
-
Kyiv, Ukrajina
- Study site 04
-
Vinnytsia, Ukrajina
- Study site 05
-
Vinnytsia, Ukrajina
- Study site 06
-
Vinnytsia, Ukrajina
- Study Site 07
-
Zaporizhzhia, Ukrajina
- Study site 09
-
-
-
-
-
Bruntal, Česko
- Study site 03
-
Ostrava, Česko
- Study site 05
-
Praha, Česko
- Study site 01
-
Praha, Česko
- Study site 04
-
Praha, Česko
- Study Site 08
-
Praha, Česko
- Study site 09
-
Uherske Hradiste, Česko
- Study site 02
-
Uherske Hradiste, Česko
- Study Site 07
-
Zlin, Česko
- Study site 06
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Subject demonstrates active RA according to the 1987 American College of Rheumatology (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA with functional class I-III for ≥6 months.
- Subject receives oral or parenteral MTX treatment for ≥12 weeks (overall), with an unchanged mode of application and stable MTX dose of ≥15 mg per week (or ≥12.5 mg per week in case of MTX intolerance), but no more than the highest locally approved dose for RA, for ≥8 weeks prior to baseline. The dose of MTX is expected to remain stable throughout the study and may be adjusted only for safety reasons. If applicable, the dose of folic acid must be unchanged for ≥8 weeks prior to baseline.
- Subject meets the following two criteria at both screening and baseline: - At least 6 swollen joints at 28-joint assessment. - At least 6 tender joints at 28-joint assessment.
- Subject has an erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) above the upper limit of normal (ULN) at screening. These tests may be repeated once during the screening period at the discretion of the investigator.
- Subject is ≥18 and ≤75 years of age.
- Subject has a body mass index ≥18 and ≤35 kg/m².
- Subject receives treatment with corticosteroids ≤10 mg prednisone equivalent, stable for at least 4 weeks prior to baseline and during the study, if applicable.
- Subject receives treatment with non-steroidal anti-inflammatory drugs (NSAIDs), stable for at least 2 weeks prior to baseline and during the study, if applicable.
- Female subjects of childbearing potential: has both a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
- Subject is judged to be in good general health as determined by the investigator based upon the results of medical history, laboratory profile, physical examination, chest X-ray (within 3 months before screening date is acceptable), and 12-lead electrocardiogram (ECG).
- Subject has a cluster of differentiation 4 (CD4) cell count of > 400/µl at screening.
Exclusion Criteria:
- Subject has previous exposure to any systemic biologic therapy (e.g., etanercept, adalimumab, rituximab, abatacept, tocilizumab), to Janus kinase (JAK) or spleen tyrosine kinase (SYK) inhibitors, or to Tregalizumab. Previous treatment with an anti-TNF agent is allowed only, if all of the following criteria apply: - treatment was stopped for reasons other than lack of efficacy or adverse events (AEs) - treatment was stopped at least 12 weeks or five half-lives of the compound prior to baseline (whichever is longer), and - the treatment period did not exceed 6 weeks.
- Subject received treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) apart from MTX in the 12 weeks prior to baseline, and for DMARD leflunomide in the 24 weeks prior to baseline (except where specific leflunomide wash-out procedures were completed, following applicable guidelines).
- Subject has been treated with intra-articular or parenteral administration of corticosteroids in the 4 weeks prior to baseline. Inhaled corticosteroids for stable medical conditions are allowed.
- Subject has undergone joint surgery in the 12 weeks prior to baseline (at joints to be assessed within the study) or has undergone major surgery (e.g., abdominal surgery) in the 8 weeks prior to baseline.
- Subject has a history of acute inflammatory joint disease of an origin other than RA or subject has any other rheumatic disease other than RA (e.g., mixed connective tissue disease, seronegative spondylarthropathy, psoriatic arthritis, Reiter's syndrome, fibromyalgia, systemic lupus erythematosus or any arthritis with onset prior to age 17 years). However, subjects may have secondary Sjögren's syndrome.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Dose Level 1 Tregalizumab
25mg Tregalizumab s.c. weekly
|
humanized anti-CD4 mAb
Ostatní jména:
|
Experimentální: Dose Level 2 Tregalizumab
100mg Tregalizumab s.c. weekly
|
humanized anti-CD4 mAb
Ostatní jména:
|
Experimentální: Dose Level 3 Tregalizumab
200mg Tregalizumab s.c. weekly
|
humanized anti-CD4 mAb
Ostatní jména:
|
Komparátor placeba: Placebo
Placebo s.c. weekly
|
identical end formulation buffer
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
The Proportion of Subjects Who Achieve an ACR20 at Week 12 Following Treatment With Tregalizumab + MTX Compared With Subjects Treated on Placebo + MTX
Časové okno: Week 12
|
The primary efficacy variable was the proportion of subjects with an ACR20 response after 12 weeks of double-blind treatment with the study medication. The analysis of the primary endpoint was performed using observed cases (OC) on the FAS. |
Week 12
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Proportions of Subjects With an ACR 20 Response.
Časové okno: Week 24
|
Week 24
|
Proportions of Subjects With an ACR 50 & 70 Response.
Časové okno: Week 12 & Week 24
|
Week 12 & Week 24
|
Proportions of Subjects With an Disease Activity Score DAS28 <2.6
Časové okno: Week 12 & Week 24
|
Week 12 & Week 24
|
Proportions of Subjects With Low Disease Activity DAS28 ≤3.2
Časové okno: Week 12 & Week 24
|
Week 12 & Week 24
|
ACR Score
Časové okno: up to 48 weeks
|
up to 48 weeks
|
Simple Disease Activity Index [SDAI] ≤11
Časové okno: week 12 & 24
|
week 12 & 24
|
Clinical Disease Activity Index [CDAI] ≤10
Časové okno: week 12 & 24
|
week 12 & 24
|
DAS28
Časové okno: up to 48 weeks
|
up to 48 weeks
|
EULAR Response
Časové okno: up to 48 weeks
|
up to 48 weeks
|
ACR Score Individual Components
Časové okno: up to 48 weeks
|
up to 48 weeks
|
DAS28 Score Individual Components
Časové okno: up to 48 weeks
|
up to 48 weeks
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Pharmacokinetics
Časové okno: up to 48 weeks
|
AUC, Cmax, Tmax at baseline, and at Week (W) 2/Visit (V) 4, W4/V5, W8/V7, W12/V8, W24/V10, W3/V122, W48 (end of Treatment [EoT]/ early termination ET), and at follow-up (post EoT/post ET).
|
up to 48 weeks
|
Evaluation of Safety, Patient Reported Outcomes & Blood Tests.
Časové okno: up to 48 weeks
|
up to 48 weeks
|
Spolupracovníci a vyšetřovatelé
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 986_TREAT 2b
- 2013-000114-38 (Číslo EudraCT)
- BT986 (Jiný identifikátor: Biotest AG)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Tregalizumab
-
T-Balance Therapeutics GmbHDokončenoAlergické astma | Alergie na roztoče domácího prachuNěmecko